Funding for this research was provided by:
F. Hoffmann-La Roche
Received: 31 July 2017
Accepted: 6 March 2018
First Online: 15 March 2018
Ethics approval and consent to participate
: Approval for the study protocol and any accompanying information provided to the patient was obtained from ethics committees at each study site (see Additional file InternalRef removed). This study was performed in accordance with the Declaration of Helsinki and the guidelines for Good Clinical Practice. Signed, informed consent was obtained from all patients prior to enrollment in the study.
: Consent for publication is not applicable.
: NAL, PA, EN, and DH are employees of Roche. EN holds shares in Roche. MS was previously an employee of Genentech during the production of this manuscript. YJB has consulted for Genentech-Roche and received institutional research grants from Genentech-Roche. VM has received speaker honoraria from Amgen, Astra Zeneca, Celgene, Daiichi-Sankyo, Eisai, Pfizer, Pierre-Fabre, Nektar, Novartis, Roche, Teva, Janssen-Cilag, has received consultancy honoraria from Genomic Health, Roche, Pierre Fabre, Amgen, Daiichi-Sankyo and Eisai, and research funding from Roche. All remaining authors have declared no conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.